Opus Genetics IRD Stock Issuance Proceeds
Stock Issuance Proceeds at other companies
Other financials
Where this comes from
Reported directly by Opus Genetics in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfCommonStock.
The official record: Opus Genetics’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Opus Genetics's stock issuance proceeds.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Opus Genetics's stock issuance proceeds?
- Opus Genetics (IRD) reported stock issuance proceeds of $2.25M in Q1 2026.
- How has Opus Genetics's stock issuance proceeds changed year-over-year?
- Opus Genetics's stock issuance proceeds increased by 450.1% year-over-year, from $409K to $2.25M.
- What is the long-term trend for Opus Genetics's stock issuance proceeds?
- Over 3 years (2021 to 2025), Opus Genetics's stock issuance proceeds has grown at a -41.2% compound annual growth rate (CAGR), from $28.49M to $5.81M.
- What does stock issuance proceeds mean?
- The total cash inflow resulting from the issuance of new common shares to investors. This is a fundamental measure of external equity financing used to support operations, debt repayment, or strategic growth initiatives.